LCM
TRDA icon

Laurion Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Laurion Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-199,066
Closed -$2.89M – 695
2023
Q1 		$2.89M Hold
199,066
– – 0.02% 261
2022
Q4 		$2.69M Hold
199,066
– – 0.01% 298
2022
Q3 		$3.14M Buy
199,066
+70,000
+54% +$889K 0.02% 292
2022
Q2 		$1.57M Buy
+129,066
New +$979K 0.02% 249

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Laurion Capital Management's TRDA Position: Q2 2023 in Review

Laurion Capital Management sold out of Entrada Therapeutics (TRDA) in Q2 2023, closing a stake of 199,066 shares — an estimated $2.89M sold.

Laurion Capital Management first reported a position in TRDA in Q2 2022 and held it in 4 quarters. The position peaked at $3.14M in Q3 2022. 56 funds tracked by Wall St. Rank hold TRDA as of Q2 2023.

  • Laurion Capital Management reported no remaining Entrada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Laurion Capital Management sold 199,066 Entrada Therapeutics shares in Q2 2023, an estimated $2.89M.
  • Laurion Capital Management first reported a position in Entrada Therapeutics in Q2 2022 and held it in 4 quarters.
  • Laurion Capital Management's Entrada Therapeutics position peaked at $3.14M in Q3 2022.
  • 56 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2023.

Based on Laurion Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.